Dong Shen, M.D., PhD., graduated from Johns Hopkins University School of Medicine, is the founder and CEO of RNAimmune. Headquartered in Gaithersburg, MD, RNAimmune’s messenger RNA proprietary technology is used to develop cancer and antibody therapies and vaccines and the company is focused on developing a mRNA vaccine for COVID-19. Dr. Shen will be interviewed by Scott Meza, Shareholder, Greenberg Traurig. Discussion will include:
• Challenges in developing a successful vaccine for COVID-19 and the prospects for success
• Collaboration on vaccine development with government and commercial entities, locally, nationally and globally
• Strategies for implementing the worldwide distribution of effective vaccines
• Impact of the pandemic on the medical research community and opportunities it has created for company growth